

Noumi Limited (ASX: NOU) Quarter ended 30 September 2023 Quarterly Activities and 4C Report:

Noumi Limited (**ASX: NOU**) (**Noumi** or the **Company**), a leading Australian FMCG company with a mission to create quality, on-trend, responsibly produced dairy and plant-based milks, nutritional products and ingredients, today releases its Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 September 2023 (unaudited) and is pleased to provide the following update on the Company's financial and operating performance.

Q1 FY2024 key features:

- Total Q1 FY2024 revenue from continuing operations of \$145.4 million was up \$11.4 million or 8.5% compared to Q1 FY2023.
- Plant-based Milks Q1 FY2024 revenue of \$44.0 million was up \$3.5 million or 8.6% compared to Q1 FY2023.
- Dairy and Nutritionals Q1 FY2024 revenue of \$101.3 million was up \$8.0 million or 8.6% compared to Q1 FY2023.
- Q1 FY2024 operating cash outflow of \$0.7 million includes legal, US litigation and transformation expenses of \$3.5 million. Excluding these expenses, Noumi delivered a positive operating cash flow of \$2.8 million.
- As at 30 September 2023, the Company's unrestricted cash position was \$16.0 million, with undrawn facilities of \$18.0 million. Combined unrestricted cash at bank and undrawn facilities total \$34.0 million.

Current trading

- Global dairy prices continue to create challenging conditions for Noumi's long-life dairy milk export sales and bulk commodities, with Australian dairy exporters at a disadvantage due to price competition from lower-cost countries. Domestic conditions for Dairy remain satisfactory, with cost increases largely offset by price increases that are beginning to be reflected in sales performance.
- Noumi remains cautious about the macro-economic environment and consumer spending in Australia in particular.

Business performance

Plant-based Milks

A leading producer of long-life plant-based products including almond, soy, oat, coconut, macadamia milk and liquid stocks.

The Plant-based Milks segment continued its growth trajectory, with revenue for Q1 FY2024 of \$44.0 million up \$3.5 million or 8.6% compared to Q1 FY2023. Milklab plant-based sales were up \$1.9 million or 7.3% in Q1 FY2024 compared to a Q1 FY2023, with continued growth in out-of-home sales, which rose 7.4%, led by Milklab Almond and introduction of a small pack format.

In the fast-growing oat milk segment, Milklab Oat continued its strong performance, with increasing distribution contributing to sales up 65.1% compared to Q1 FY2023.

New products across the Australia's Own plant-based portfolio also contributed to the positive result.

Private label sales were up 24.9% in Q1 FY2024 compared to a Q1 FY2023, with new supply agreements and strong demand in the domestic retail channel.

Dairy and Nutritionals

A leading producer of long-life dairy milk, nutritional products and performance powders.

Total Dairy and Nutritionals revenue increased to \$101.3 million, up \$8.0 million or 8.6% compared to Q1 FY2023, largely reflecting the positive impact of higher prices in domestic retail markets to offset the significant rises in farmgate milk prices.

Dairy UHT sales to domestic retail customers were up 24.9% compared to Q1 FY2023, with out-of-home dairy UHT sales up 31.9%. Dairy UHT sales to export markets were down 9.9% compared to Q1 FY2023, reflecting the planned reduction in low-margin export market volumes and price competition from other international suppliers.

Consumer Nutritionals sales were down 4.3% compared to Q1 FY2023, with strong growth in Vital Strength and a rise in Uprotein sales through e-commerce channels offsetting a fall in Crankt sales.

Total Nutritional Ingredients sales were up 3.8% compared to Q1 FY2023, with Lactoferrin sales up 21.2%. This was offset by an 18.7% reduction in Bulk Nutritional ingredients, reflecting lower prices in competitive export markets.

Appendix 4C cashflow report – released with this activity report

- Q1 FY2024 operating cash flow was negative \$0.7 million. This includes legal, US litigation and transformation expenses of \$3.5 million. Excluding these expenses, Noumi delivered a positive operating cash flow of \$2.8 million in Q1 FY2024.
- Capital expenditure investments of \$1.0 million in property plant and equipment were recorded during Q1 FY2024.
- At Q1 FY2024 close, the Company had \$472.4 million of available finance facilities, of which \$454.4 million was drawn.
- The Company elected to pay interest-in-kind amounting to \$7.4 million on Convertible Notes for Q1 FY2024, of which \$3.2 million is attributable to related party investors.

Related party payments – Current Quarter (July 2023 to September 2023)

Payment to	Nature of Payment	Amount (A\$)
Independent Directors	Director fees	138,145
Non-Independent Directors	Director fees	81,379
Michael Perich – CEO	Employment costs	192,685
Australian Fresh Milk Trading P/L	Milk purchases	3,336,960
Perich Property Holdings P/L	Rent and outgoings	907,250
Perich Property Unit Trust	Rent and outgoings	2,180,983

Leppington Pastoral Co P/L	Directors' indemnity recharges	162,149
	Q1 FY2024 Total	<u>6,999,551</u>

Details of payments to related parties of the entity and their associates in item 6 of Appendix 4C have been solely assessed in accordance with Australian Accounting Standards.

Note to Market

None of the information included in this announcement should be considered individually material, unless specifically stated. All figures in this announcement are provided on an unaudited basis.

This Company presentation may include certain statements, estimates or projections with respect to the anticipated future performance of the Company, and any ongoing or future projects or both. Those statements, estimates or projections are based on assumptions about future events and management actions that may not necessarily take place and are subject to significant uncertainties, many of which are outside the control of the Company. Those assumptions may, or may not, prove correct. No representation is made as to the accuracy of those statements, estimates or projections.

- END -

Investor contact:

Justin Coss Company Secretary Tel: +61 2 9526 2555 Noumi Limited justin.coss@noumi.com.au	Clive Mathieson Cato & Clive Tel: +61 411 888 425 clive@catoandclive.com
---	---

The release of this announcement was authorised by the Board of Directors.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Noumi Limited

ABN

41 002 814 235

Quarter ended ("current quarter")

30 September 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	142,687	142,687
1.2 Payments for		
research and development	(180)	(180)
product manufacturing and operating costs	(117,152)	(117,152)
advertising and marketing	(6,253)	(6,253)
leased assets	(2,557)	(2,557)
staff costs	(8,695)	(8,695)
administration and corporate costs	(3,763)	(3,763)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	363	363
1.5 Interest and other costs of finance paid	(2,546)	(2,546)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (legal and US litigation costs)	(2,591)	(2,591)
1.9 Net cash from / (used in) operating activities	(687)	(687)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
entities	-	-
businesses	-	-
property, plant and equipment	(1,038)	(1,038)
investments (security deposit)	-	-
intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	other non-current assets (software)	(212)	(212)
2.2	Proceeds from disposal of:		
	entities	-	-
	businesses	-	-
	property, plant and equipment	-	-
	investments	-	-
	intellectual property	-	-
	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (proceeds from security deposit)	1,690	1,690
2.6	Net cash from / (used in) investing activities	440	440

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(1,912)	(1,912)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (lease payments)	(418)	(418)
3.10	Net cash from / (used in) financing activities	(2,330)	(2,330)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	18,561	18,561
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(687)	(687)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	440	440

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(2,330)	(2,330)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	15,984	15,984

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	15,984	18,561
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	15,984	18,561

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	7,000
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	472,390	454,390
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	472,390	454,390

7.5 **Unused financing facilities available at quarter end** 18,000

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

7.6 Loan Drawn Facilities	000's	Average Interest Rate	Latest Maturity Date	Secured/ Unsecured
Recourse Debtor Finance Facilities				
HSBC	13,875	7.60%	rolling 6 months	Secured
Convertible Notes				
Various ¹	353,224	8.50%	27-May-27	Secured
Revolver Finance Facilities				
HSBC & NAB	28,000	8.44%	4-Jul-25	Secured
Finance Leases				
NAB	46,205	4.66%	Feb-27	Secured
Tetra Pak	7,630	4.50%	Jan-27	Secured
Energy Ease	3,506	6.52%	Mar-27	Secured
Dankse Bank	165	4.18%	Feb-24	Secured
Bank of Queensland	97	4.09%	Oct-26	Secured
ChemClean	1,172	5.37%	Jul-25	Secured
Toyota	508	3.25%	Jun-25	Secured
Other	9	4.20%	Feb-24	Secured
454,390				

¹The carrying amount of the convertible notes recorded on 30 June 2023 statutory accounts in accordance with the accounting standards is \$295.5m. The above-mentioned loan facilities amount contains principal of \$292.0m and capitalised interest (Paid in Kind) of the convertible notes at 30 September 2023 of \$61.2m.

The Group's primary bank facilities are with HSBC Bank Australia Limited (HSBC) and National Australia Bank (NAB). They include an undrawn \$18m syndicated facility, equipment financing facilities (NAB) and debtor financing facilities (HSBC). The Group also has other bi-lateral equipment finance facilities from a number of financiers and other general transactional banking facilities.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(687)
8.2 Cash and cash equivalents at quarter end (item 4.6)	15,984
8.3 Unused finance facilities available at quarter end (item 7.5)	18,000
8.4 Total available funding (item 8.2 + item 8.3)	33,984
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	49.5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 October 2023

Authorised by: 
The Board of Directors